We demonstrate that BTBD10 is associated with TILs and immune checkpoints, and we illustrate the molecular mechanism by which BTBD10 acts as an independent risk factor in disease progression in HCC patients. This evidence concerns the gene BTBD10 and hepatocellular carcinoma.